The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > POZEN Inc.

POZEN Inc.
Nasdaq: POZN
Change
symbol:
     
 PROFILE
POZEN is a heady business. The development-stage company's primary product candidates, MT 100 and MT 300, are being developed as oral and injectable treatments, respectively, for migraine headaches. Other pharmaceutical products in the pipeline include MT 500, which blocks receptors in the brain that are implicated in migraines, and MT 400, a migraine treatment that combines two commercially available drugs. The company has a licensing agreement with Hoffmann-La Roche for MT 500 and plans to establish similar agreements with other pharmaceutical firms.

 COMPETITION
Abbott Laboratories (ABT)
Interneuron Pharmaceuticals, Inc. (IPIC)

 STOCK ANALYSIS
 View by:
 Day 
 Day 
 Month 
 Month 
 Year 
 Year 
FURTHER ANALYSIS
• Advanced Charting
• Deals

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 0.10
Employees: 20
Revenue per employee: $5,000.00

 KEY PEOPLE
• John R. Plachetka
    CEO
• Matthew E. Czajkowski
    CFO

 CONTACT INFO
6330 Quadrangle Dr., Ste. 240
Chapel Hill, NC 27514
US
Phone: 919-490-0012
Fax: 919-490-5552
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001